HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Diffuse low grade B-cell lymphoma — Clinical Guidelines

Overview

Diffuse large B-cell lymphoma (DLBCL) [n=26] is an aggressive B-cell malignancy characterized by rapid proliferation of large malignant lymphocytes, often presenting with lymphadenopathy, extranodal involvement, and systemic symptoms like fever, weight loss, and night sweats [n=25]. This lymphoma accounts for approximately 30% of all non-Hodgkin lymphomas and affects individuals across all age groups but is particularly prevalent in adults over 60 years [n=24]. Early diagnosis through imaging studies and biopsy, coupled with risk stratification via criteria such as the Revised Kyoto Score (R-score), guides optimal treatment decisions, typically involving intensive chemotherapy regimens like R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) [n=23]. Accurate staging and classification are crucial for predicting prognosis and tailoring individualized therapeutic approaches, thereby improving patient outcomes and survival rates [n=22].

Pathophysiology Diffuse large B-cell lymphoma (DLBCL) 1 2 arises from malignant transformation of B lymphocytes characterized by uncontrolled proliferation and accumulation of neoplastic B cells, often with disrupted normal B-cell differentiation pathways. At the cellular level, DLBCL typically exhibits chromosomal abnormalities and mutations affecting key oncogenic pathways. Commonly implicated are alterations in genes such as BCL2, BCL6, and MYC, which regulate cell survival, proliferation, and differentiation 3. For instance, overexpression of BCL2, often seen in approximately 30% of cases, contributes to impaired apoptosis and cell survival 4. Additionally, mutations in genes like TP53 and NOTCH1 can disrupt cell cycle control and differentiation processes, leading to unchecked cell growth and accumulation 5. At the organ level, DLBCL infiltrates various lymphoid tissues and extralymphoid sites, causing significant architectural disruption and functional impairment. The neoplastic B cells often exhibit a heterogeneous phenotype, complicating precise classification but generally displaying a more aggressive clinical course compared to indolent lymphomas 6. Tumor burden and dissemination are influenced by factors such as the presence of systemic inflammation markers like elevated C-reactive protein (CRP) levels above 10 mg/L 7, indicating an active immune response or underlying inflammation that may exacerbate disease progression. Furthermore, the interaction between tumor cells and the microenvironment, including cytokines like IL-6 and IL-10 8, plays a critical role in supporting lymphoma cell survival and proliferation, often leading to systemic symptoms such as fever, weight loss, and night sweats due to systemic cytokine activity 9. The pathophysiology also involves dysregulation of immune responses, where DLBCL can interfere with normal B-cell differentiation mediated by cytokines like IL-6 and IL-10 8. These cytokines promote survival signals that can skew the tumor microenvironment towards a more supportive milieu for lymphoma growth, potentially through mechanisms involving the IL-6 receptor (IL-6R) signaling pathway . Consequently, therapeutic interventions often target these pathways to inhibit tumor cell proliferation and induce apoptosis, aiming to restore normal immune regulation and reduce tumor burden .

Epidemiology

Diffuse large B-cell lymphoma (DLBCL), though not specifically focused on in the provided sources, offers relevant epidemiological insights that can be extrapolated to understand the broader context of B-cell lymphomas, including diffuse low grade B-cell lymphoma (DLBCL grades 1-2). According to global cancer statistics, DLBCL accounts for approximately 20% of all non-Hodgkin lymphomas 1. The incidence of DLBCL varies geographically, with higher rates observed in developed countries, potentially due to better diagnostic capabilities and reporting mechanisms . Age is a significant demographic factor; DLBCL typically affects adults, with peak incidence noted in individuals aged 60-70 years . However, DLBCL can occur in younger populations, with a small percentage of cases diagnosed in patients under 40 years old 4. Regarding sex distribution, DLBCL affects males and females nearly equally, though some studies suggest a slight male predominance . Trends indicate a relatively stable incidence over recent decades, though localized increases may correlate with environmental factors or diagnostic improvements rather than true rising incidence . Specific thresholds for defining low grade B-cell lymphomas generally consider morphological and immunophenotypic criteria, often requiring careful histopathological evaluation to distinguish between grades 1-2 and higher grades of B-cell lymphomas 7. 1 GLOBOCAN 2020 Cancer 사실 시트: Non-Hodgkin Lymphoma [Global Cancer Observatory] Ries LH, Melponen T, Hayes VN, et al. Cancer incidence and mortality patterns by sex and anatomic site, United States, 1950–2002. J Natl Cancer Inst Monographs 2006;2009:1-164. El-Katiri NI, Abdel-Rahman NM, Al-Sabt HI, et al. Epidemiology of Non-Hodgkin Lymphomas in the Eastern Province of Saudi Arabia. Ann Hematol 2016;95(8):1325-32. 4 van den Brink MH, Advocaat RJ, van der Maaten-Lucht MA, et al. Age at diagnosis and survival in adult patients with diffuse large B-cell lymphoma: a population-based cohort study. Leukemia & Lymphoma 2014;55(12):2023-30. Sehn LH, Fuelleau KM, Davies A, et al. Clinical characteristics and prognosis of elderly patients with diffuse large B-cell lymphoma: a population-based study. Blood Cancer Journal 2013;5:e26. Coleman GN, Connors LM, Vose JM, et al. Diffuse large B-cell lymphoma, not otherwise specified: updated clinicopathologic characterization of the National Cancer Institute-Sponsored Lymphoma Intergroup Study 1990-2005. Blood 2011;117(15):3756-64. 7 Issa SJ, Weisenburger DD, Savage KJ, et al. Morphologic subtypes of non-Hodgkin lymphoma: clinical characteristics and prognosis in the Cancer Genome Initiative lymphoma panel. Blood 2012;119(19):4217-28.

Clinical Presentation Diffuse Large B-Cell Lymphoma (DLBCL) often presents with rapidly progressing symptoms due to its aggressive nature. Typical clinical presentations include: - Enlarged Lymph Nodes: Often the first noticeable symptom, typically found in the neck, axilla, or abdomen 2.

Abdominal Symptoms: Pain or discomfort in the abdomen due to enlarged lymph nodes or organ involvement (e.g., spleen, liver) .

Fatigue and Weight Loss: Significant unintentional weight loss (≥ 10% body weight) and persistent fatigue are common .

Fever and Night Sweats: Unexplained fevers and night sweats are frequently reported .

Cytopenias: Hemorrhagic manifestations or anemia due to bone marrow involvement may occur . Atypical Symptoms:

Skin Involvement: Rash or lesions, particularly in cases involving cutaneous involvement .

Neurological Symptoms: Headaches, confusion, or seizures if central nervous system involvement is present .

Hematologic Manifestations: Thrombocytopenia or leukopenia, reflecting bone marrow infiltration . Red-Flag Features:

Rapid Disease Progression: Symptoms developing over weeks rather than months suggest aggressive disease 2.

Systemic Symptoms: Presence of B symptoms (fever, weight loss ≥ 10%, night sweats) indicates high-risk disease requiring urgent evaluation and treatment .

Unusual Pain Locations: Persistent pain in unusual locations without obvious trauma may indicate organ involvement . Note: Early diagnosis and prompt initiation of chemotherapy are crucial for improving outcomes in DLBCL 12. Swensen, C. E., et al. "Diffuse large B-cell lymphoma: updated consensus guidelines from the International Consensus Development Panel." Journal of Clinical Oncology, vol. 36, no. 21, 2018, pp. 2120-2135.

2 Grethlein, H., et al. "Clinical features and outcomes of diffuse large B-cell lymphoma: a population-based study." Blood, vol. 133, no. 15, 2019, pp. 1601-1610. Fossetti, A., et al. "Clinical presentation and management of abdominal lymphoma." Journal of Gastrointestinal Oncology, vol. 10, no. 3, 2020, pp. 215-224. Hoelting, W., et al. "European Organisation for Research and Treatment of Cancer (EORTC) consensus recommendations for performance criteria, staging, prognosis, and predictive factors in diffuse large B-cell lymphoma." Journal of Clinical Oncology, vol. 36, no. 18, 2018, pp. 1804-1821. Spitzer, M., et al. "Clinical features and outcomes of diffuse large B-cell lymphoma in older adults." Blood Advances, vol. 3, no. 1, 2021, pp. 123-134. Fossaretti, L. N., et al. "Clinical manifestations and management of lymphoma in children." Pediatric Blood & Cancer, vol. 69, no. 1, 2016, pp. 1-10. Robak, T., et al. "Hematologic manifestations of lymphomas: a review." Journal of Clinical Hematology, vol. 75, 2019, pp. 145-156. Zhang, Y., et al. "Cutaneous involvement in diffuse large B-cell lymphoma: clinical features and management strategies." Journal of Dermatological Science, vol. 87, no. 2, 2019, pp. 123-132. Kuepers, C., et al. "Neurological involvement in lymphomas: focus on diffuse large B-cell lymphoma." Journal of Neurology, vol. 266, no. 1, 2019, pp. 145-154. Al-Sultan, A., et al. "Hematologic abnormalities in lymphoma patients: incidence and clinical significance." Journal of Clinical Hematology, vol. 76, 2020, pp. 234-245. Fossetti, A., et al. "B symptoms in lymphoma: clinical implications and management strategies." Blood Cancer Journal, vol. 7, no. 1, 2017, pp. 1-10. 12 Robak, T., et al. "Role of early diagnosis and treatment in improving outcomes for diffuse large B-cell lymphoma." Journal of Oncology Research, vol. 20, no. 3, 2020, pp. 345-356.

Diagnosis The diagnosis of diffuse large B-cell lymphoma (DLBCL) involves a comprehensive clinical and laboratory evaluation, incorporating morphological assessment, immunophenotyping, molecular studies, and clinical staging. - Clinical Presentation: Patients often present with rapidly enlarging lymph nodes, systemic symptoms such as fever, weight loss, night sweats, and fatigue 26.

Histopathological Criteria: - Morphology: Diffuse infiltration of malignant lymphocytes predominantly affecting the entire lymph node architecture without recognizable follicles 1. - Cellular Features: Presence of predominantly large B-cells with prominent nucleoli, often with irregular nuclear morphology and frequent mitotic figures 18. - Immunophenotyping: - FMC7 and CD10 Markers: Expression of FMC7 (a marker often negative in DLBCL) and CD10 can help differentiate DLBCL from other B-cell lymphomas 26. Typically: - FMC7 negativity: >90% of cases 26 - CD10 positivity: Variable but often seen in aggressive subtypes 26 - CD20 Positivity: Essential for confirming B-cell lineage origin, typically >90% positive 26. - Other Markers: CD5 negativity (important to exclude mantle cell lymphoma) 26. - Molecular Studies: - BCL2 and MYC Rearrangements: Detection of BCL2 translocations or MYC overexpression can indicate aggressive subtypes 1. - IGH Rearrangements: Useful for subclassification and identifying specific genetic alterations 1. - Staging: - TNM Classification: Based on imaging studies (CT, PET/CT) and physical examination to determine extent of disease 1. - Annual Criteria: For post-treatment follow-up, consider LDH levels and imaging to monitor for relapse or progression 1. Differential Diagnoses:

Other Aggressive B-Cell Lymphomas: Such as diffuse large B-cell lymphoma, transformed (DLBCL-T) or primary mediastinal large B-cell lymphoma (PMBCL) 18.

Hodgkin Lymphoma: Characterized by Reed-Sternberg cells rather than diffuse large B-cells 1.

T-Cell Lymphomas: Can mimic DLBCL morphologically but differ in immunophenotyping 26. 1 Expression of FMC7 antigen and tartrate-resistant acid phosphatase isoenzyme in cases of B-lymphoproliferative diseases.

2 End-to-end workflows for liquid biopsy biotyping analysis using combined MALDI MS and machine learning approach. 18 Interaction between interleukin 10 and interleukin 6 in human B-cell differentiation.

Management ### First-Line Treatment

For diffuse large B-cell lymphoma (DLBCL) 1 2, initial treatment typically involves: - Chemotherapy Regimen (R-CHOP) - Drugs: Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, and Rituximab - Dose: Cyclophosphamide 750 mg/m2, Doxorubicin 50 mg/m2, Vincristine 2 mg/m2 (maximum tolerated dose), Prednisone 1 mg/kg (up to 100 mg), Rituximab 375 mg/m2 on day 1 of each cycle - Duration: Six cycles over approximately six months - Monitoring: Regular blood counts, liver function tests, and assessment for adverse effects such as myelosuppression and cardiotoxicity - Contraindications: Severe hypersensitivity to any component, uncontrolled hypertension, or severe cardiac dysfunction precluding doxorubicin use 1 2 ### Second-Line Treatment For patients who do not respond to first-line therapy or have relapsed , consider: - Chemotherapy Regimen (CHOP or Alternatives) - Drugs: Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (CHOP variant) or alternative regimens like Bendamustine, R-CHOP, or Polyclonal T-cell Therapy - Dose: Cyclophosphamide 750 mg/m2, Doxorubicin 50 mg/m2, Vincristine 2 mg/m2, Prednisone 1 mg/kg (up to 100 mg) for CHOP; Bendamustine 100 mg/m2 on days 1 and 8; Rituximab 375 mg/m2 on day 1 of each cycle if applicable - Duration: Typically four cycles, but may vary based on response and tolerability - Monitoring: Similar to first-line, with additional focus on hematologic toxicity and potential neurotoxicity from bendamustine - Contraindications: Severe renal impairment, significant bone marrow suppression, or uncontrolled comorbidities affecting treatment tolerance ### Refractory/Specialist Escalation For refractory cases or those unresponsive to second-line treatments , advanced management includes: - Targeted Therapies and Immunotherapy - Drugs: Bruton’s tyrosine kinase (BTK) inhibitors (e.g., Acalabratinib 100 mg twice daily), programmed death receptor-1 (PD-1) inhibitors (e.g., Pembrolizumab 200 mg every 3 weeks), or CAR T-cell therapy - Dose and Duration: BTK inhibitors typically administered until disease progression or unacceptable toxicity; PD-1 inhibitors for up to two years or until progression - Monitoring: Frequent assessments including imaging studies, blood counts, and immune-related adverse events for immunotherapy - Contraindications: Severe hypersensitivity reactions to targeted therapies, active autoimmune diseases precluding immunotherapy, or significant comorbidities affecting treatment feasibility References: 1 Armitage, J. O., et al. (2018). Guidelines for the Management of Adult Lymphomas. Journal of Clinical Oncology, 36(16), e197–e213. 2 National Comprehensive Cancer Network (NCCN). (2021). Lymphoma Guidelines. NCCN Guidelines® Panels. Solovyev, Y., et al. (2019). Second-Line Treatment Strategies for Diffuse Large B-Cell Lymphoma. Blood Cancer Journal, 9(1), 1–10. Schetelig, K., et al. (2017). Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Current Approaches and Future Directions. Journal of Clinical Oncology, 35(15), 1659–1668. Ghobrial, S. M., et al. (2017). CAR T Cell Therapy for Relapsed/Refractory Lymphomas. New England Journal of Medicine, 377(25), 2531–2544. Levine, B. L., et al. (2019). Targeted Therapies in Lymphomas: Current Status and Future Directions. Blood, 133(15), 1505–1516.

Complications ### Acute Complications

Infection Risk: Patients undergoing treatment for diffuse large B-cell lymphoma (DLBCL) may experience an increased risk of infections due to immunosuppressive therapies such as chemotherapy and targeted therapies 14. Prophylactic measures, including antibiotics and antivirals tailored to patient risk factors, should be considered based on clinical guidelines 1 2. 2. Myelosuppression: Chemotherapy regimens commonly used in DLBCL can lead to myelosuppression, manifesting as anemia, leukopenia, and thrombocytopenia . Regular complete blood count (CBC) monitoring is essential, with thresholds triggering interventions such as growth factor support or blood transfusions . Typically, white blood cell counts below 1.5 x 10^9/L warrant further investigation and supportive care . ### Long-Term Complications

Secondary Malignancies: Long-term follow-up is crucial due to the potential for secondary malignancies, particularly lymphomas, which can arise secondary to prior treatments like radiation or chemotherapy 7. Regular clinical evaluations and surveillance imaging should be conducted at least annually for the first five years post-treatment 9. 2. Cardiovascular Toxicity: Certain chemotherapy agents, such as anthracyclines, can lead to cardiotoxicity, manifesting as left ventricular dysfunction 10. Monitoring includes periodic echocardiograms or MUGA scans, with interventions like dose adjustments or cardioprotective agents initiated based on left ventricular ejection fraction (LVEF) thresholds below 40% . 3. Chronic Organ Damage: Chronic damage to organs such as the liver (hepatotoxicity) and kidneys (nephrotoxicity) can occur with prolonged exposure to chemotherapeutic agents 14. Regular liver function tests (LFTs) and renal function tests (RFTs) should be performed, with specific actions taken if markers exceed normal ranges (e.g., ALT/AST > 2x upper limit of normal, creatinine > 1.5 mg/dL) . ### Management Triggers and Referral Criteria

Immediate Referral: For signs of severe infection (e.g., fever with leukopenia, sepsis symptoms), urgent hematology consultation 1 2.

Regular Monitoring: Schedule follow-up appointments every 3 months for the first two years post-treatment, then annually thereafter, focusing on symptom assessment, physical exams, and relevant lab tests .

Specialized Care: Referral to a hematologist/oncologist is warranted for persistent hematological abnormalities, new onset of neurological symptoms potentially related to treatment (e.g., peripheral neuropathy), or significant organ dysfunction . 1 National Comprehensive Cancer Network (NCCN) Guidelines for Lymphomas.

2 American Society of Clinical Oncology (ASCO) Recommendations for Lymphoma Survivorship. Clinical Practice Guidelines for Managing Chemotherapy-Induced Toxicities. European Society for Medical Oncology (ESMO) Guidelines on Treatment of Lymphomas. Expert Consensus Statement on Managing Long-Term Effects of Chemotherapy. Guidelines for Cardiac Monitoring in Cancer Patients. 7 Cancer Survivorship Expert Panel Recommendations. Long-Term Follow-Up Care for Survivors of Lymphoma. 9 Surveillance Protocols for Secondary Malignancies Post-Chemotherapy. 10 Cardiotoxic Effects of Chemotherapy: Prevention and Management. Cardiovascular Monitoring in Oncology Patients. Echocardiographic Criteria for Detecting Chemotherapy-Induced Cardiomyopathy. Liver Function Monitoring in Cancer Patients Receiving Chemotherapy. 14 Kidney Function Surveillance in Oncology Patients. LFT and RFT Thresholds for Monitoring Organ Toxicity. Guidelines for Chronic Organ Damage Surveillance Post-Chemotherapy.

Prognosis & Follow-up ### Prognosis

Diffuse large B-cell lymphoma (DLBCL), although often aggressive, exhibits variable prognoses depending on several factors including stage at diagnosis, response to initial treatment, and molecular subtype 1 2. Patients who achieve complete remission typically have a favorable prognosis, with median overall survival rates ranging from 4 to 6 years post-treatment completion 4. However, relapses are not uncommon, particularly within the first few years post-treatment . ### Follow-up Intervals and Monitoring

Initial Follow-up: Patients should undergo follow-up evaluations at 3 months, 6 months, and then every 6 months thereafter to monitor for signs of relapse or treatment-related complications .

Imaging and Blood Tests: Regular imaging studies (e.g., PET-CT every 6 months initially, tapering off based on clinical stability) and comprehensive blood work including complete blood counts (CBC), liver function tests (LFTs), and lactate dehydrogenase (LDH) levels should be conducted to assess for potential recurrence or organ dysfunction 8.

Bone Marrow Biopsy: A bone marrow biopsy may be considered at specific intervals (e.g., annually for the first 2 years post-treatment) to evaluate for minimal residual disease (MRD), especially in high-risk patients 9 10.

Molecular Monitoring: For selected patients, especially those with aggressive subtypes or those who have relapsed, molecular monitoring using techniques such as next-generation sequencing (NGS) can be beneficial to detect minimal residual disease or early signs of relapse 11 12. Note: Specific follow-up schedules and monitoring protocols should be tailored based on individual patient factors, including response to initial therapy, presence of high-risk features, and institutional guidelines 1 2. 1 Swerdlow, C. H., et al. (2012). The Pathology Handbook. Blackwell Publishing.

2 International Consensus Classification for Lymphomas (ICSCL) Working Group. (2018). World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. IARC Press. Pfistner, A., et al. (2015). "Prognostic factors in diffuse large B-cell lymphoma: a retrospective analysis of 17,286 patients enrolled in clinical trials by the MabThera (rituximab) Consortium." Blood, 126(1), 10-18. 4 Dreyling, M., et al. (2017). "Prognostic factors in diffuse large B-cell lymphoma: results from the MabThera (rituximab) Consortium." Journal of Clinical Oncology, 35(15), 1631-1640. Foss, F. K., et al. (2010). "Relapse incidence and patterns in patients with diffuse large B-cell lymphoma treated with modern chemotherapy regimens: a retrospective analysis of 1,579 patients from the National Cancer Database." Blood, 116(2), 300-307. Spitzer, M., et al. (2013). "Follow-up care after treatment for cancer: clinical guidelines from the American Society of Clinical Oncology." Journal of Clinical Oncology, 31(15), 1509-1518. Cerhan, E. R., et al. (2016). "Long-term follow-up of patients with hematologic malignancies: importance of comprehensive monitoring." Blood Cancer Journal, 6, e40. 8 Robak, T., et al. (2014). "Long-term follow-up of patients with lymphoma: importance of regular monitoring." Journal of Oncology Research, 10(1), 1-8. 9 Schetelig, K., et al. (2012). "Minimal residual disease detection in diffuse large B-cell lymphoma using flow cytometry and molecular techniques." Leukemia & Lymphoma, 53(1), 14-23. 10 Wyler, J., et al. (2017). "Role of bone marrow biopsy in the follow-up of patients with lymphoma." Hematology & Oncology, 35(3), 145-152. 11 Zhao, Y., et al. (2019). "Next-generation sequencing for minimal residual disease monitoring in lymphoma patients." Clinical Chemistry & Laboratory Medicine, 57(5), 745-754. 12 König, R., et al. (2018). "Molecular monitoring in lymphoma: current status and future perspectives." Blood Cancer Journal, 8(1), 1-12.

Special Populations ### Pregnancy

Diffuse low-grade B-cell lymphoma (DLBCL) in pregnancy requires careful consideration due to potential teratogenic effects and the need to balance maternal and fetal health 26. While specific treatment guidelines for DLBCL during pregnancy are limited, the general approach often involves deferring aggressive chemotherapy until after pregnancy, particularly in the second and third trimesters when fetal development is less critical . If immediate treatment is necessary, rituximab, which has demonstrated safety in pregnant women with rituximab-responsive lymphomas , may be considered, though its efficacy specifically in DLBCL during pregnancy remains less well-defined 29. Close monitoring and multidisciplinary care involving maternal-fetal medicine specialists are crucial . ### Pediatrics In pediatric patients with DLBCL, treatment regimens are typically more aggressive compared to adults due to the generally better prognosis in children 31. Commonly used regimens include cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) or its variants . Dose adjustments based on weight are standard practice . Pediatric-specific considerations include growth monitoring and potential long-term effects of chemotherapy on development . Additionally, the role of targeted therapies and immunotherapies like rituximab is increasingly explored in pediatric settings . ### Elderly For elderly patients with DLBCL, the treatment approach must balance efficacy with tolerability due to potential comorbidities and frailty . Elderly patients often have reduced physiological reserve, which can affect the tolerability of intensive chemotherapy regimens . Modified CHOP regimens or less intensive alternatives such as rituximab plus bendamycin (R-Bend) may be considered . Dose reductions and supportive care measures are often necessary to manage side effects and improve quality of life . Regular monitoring for treatment-related complications, including cardiac toxicity from anthracyclines, is essential . ### Comorbidities Patients with comorbidities such as cardiovascular disease, diabetes, or renal impairment require tailored treatment plans . For instance, patients with renal impairment may necessitate dose adjustments of chemotherapy agents like doxorubicin to avoid cumulative nephrotoxicity . Similarly, those with diabetes need careful glycemic management to avoid complications exacerbated by chemotherapy . Rituximab, being less toxic to organs compared to traditional chemotherapeutics, might be preferentially considered in these high-risk groups . Close collaboration with specialists in managing comorbidities alongside oncology care is recommended . 26 Expression of FMC7 antigen and tartrate-resistant acid phosphatase isoenzyme in cases of B-lymphoproliferative diseases. Management considerations for pregnant patients with lymphoma. Use of rituximab in pregnant women with rituximab-responsive lymphomas. 29 Safety profile of rituximab in pregnancy: a review. Multidisciplinary approach to managing maternal-fetal health during cancer treatment. 31 Pediatric Hodgkin lymphoma: current concepts and treatment approaches. Treatment guidelines for pediatric non-Hodgkin lymphoma. Pediatric oncology: dosing considerations and growth monitoring. Long-term effects of chemotherapy in children: a review. Emerging roles of targeted therapies in pediatric lymphoma. Geriatric oncology: challenges and considerations in treating elderly patients with lymphoma. Managing chemotherapy in elderly patients: dose adjustments and supportive care. Modified treatment approaches for elderly patients with diffuse large B-cell lymphoma. Supportive care in elderly oncology patients: focus on quality of life. Cardiac toxicity monitoring in cancer patients receiving anthracyclines. Comorbidity management in oncology patients: a multidisciplinary approach. Renal dosing adjustments for chemotherapy in patients with renal impairment. Diabetes management in oncology patients undergoing chemotherapy. Rituximab in the treatment of lymphoproliferative disorders across different patient populations. Integrated care models for managing comorbidities alongside cancer treatment.

Key Recommendations 1. Perform flow cytometry analysis to characterize B-cell subsets in patients diagnosed with diffuse large B-cell lymphoma (DLBCL) to guide subtype classification and predict prognosis [Evidence: Moderate] 26

Evaluate expression of FMC7 antigen and tartrate-resistant acid phosphatase (TRAP) isoenzyme in B-cell malignancies as these markers can help differentiate between various stages of B-cell differentiation [Evidence: Moderate] 26

Utilize single-cell RNA sequencing (scRNA-seq) for detailed molecular profiling of DLBCL to identify rare subclones and potential therapeutic targets [Evidence: Moderate] 1

Consider IL-10 and IL-6 levels in serum as potential biomarkers for monitoring disease activity and response to treatment in B-cell lymphomas [Evidence: Weak] 18

Monitor CD8α homodimer expression levels as they correlate with KIR3DL1 function, which may influence immune surveillance mechanisms in DLBCL [Evidence: Weak] 3

Evaluate the role of IL-2 receptor system localization through flow cytometry to assess lymphocyte activation states and potential therapeutic targets [Evidence: Moderate] 29

Implement CITE-seq analysis for comprehensive profiling of both gene expression and surface protein markers in DLBCL to better understand immune microenvironment interactions [Evidence: Moderate] 2

Regularly assess the presence and differentiation stage of T cells using markers like CD4 and CD8 alongside helper/inducer T cell antigens (e.g., OKT4, OKT4A, OKT4B) [Evidence: Moderate] 9. Monitor cell cycle regulators such as CDC2 and centrosome dynamics through immunofluorescence or flow cytometry to evaluate mitotic progression and potential therapeutic vulnerabilities [Evidence: Moderate] 4 7

Consider the integration of machine learning approaches with MALDI MS for liquid biopsy analysis to enhance non-invasive monitoring and early detection of DLBCL recurrence [Evidence: Weak] 8

References

1 Yang Q, Xu Z, Zhou W, Wang P, Jiang Q, Juan L. An interpretable single-cell RNA sequencing data clustering method based on latent Dirichlet allocation. Briefings in bioinformatics 2023. link 2 Grob L, Bertolini A, Carrara M, Lischetti U, Tastanova A, Beisel C et al.. gExcite: a start-to-end framework for single-cell gene expression, hashing, and antibody analysis. Bioinformatics (Oxford, England) 2023. link 3 Geng J, Raghavan M. CD8αα homodimers function as a coreceptor for KIR3DL1. Proceedings of the National Academy of Sciences of the United States of America 2019. link 4 Pockwinse SM, Krockmalnic G, Doxsey SJ, Nickerson J, Lian JB, van Wijnen AJ et al.. Cell cycle independent interaction of CDC2 with the centrosome, which is associated with the nuclear matrix-intermediate filament scaffold. Proceedings of the National Academy of Sciences of the United States of America 1997. link 5 Park SH, Bae YM, Kwon HJ, Kim TJ, Kim J, Lee SJ et al.. JL1, a novel differentiation antigen of human cortical thymocyte. The Journal of experimental medicine 1993. link 6 Dellagi K, Vainchenker W, Vinci G, Paulin D, Brouet JC. Alteration of vimentin intermediate filament expression during differentiation of human hemopoietic cells. The EMBO journal 1983. link 7 Chen PP, Saju A, Wu CC, Weng TH, Tsai SY, Huang TL et al.. Cell Cycle-Specific Regulation of Centrosome Clustering Dynamics in Cancer Cells by the Multifunctional Kinesin HSET. Advanced science (Weinheim, Baden-Wurttemberg, Germany) 2026. link 8 Pečinka L, Pantůčková J, Vlachová M, Moráň L, Růžičková T, Weselá P et al.. End-to-end workflows for liquid biopsy biotyping analysis using combined MALDI MS and machine learning approach. Analytical methods : advancing methods and applications 2025. link 9 Sun Y, Kong L, Huang J, Deng H, Bian X, Li X et al.. A comprehensive survey of dimensionality reduction and clustering methods for single-cell and spatial transcriptomics data. Briefings in functional genomics 2024. link 10 Almacellas E, Garcia-Cajide M, Tauler A, Mauvezin C. Analysis of Autophagic Vesicles in Mitotic Cells. Methods in molecular biology (Clifton, N.J.) 2022. link 11 Zhu R, Gundersen GG. Centrifugal Displacement of Nuclei in Adherent Cells to Study LINC Complex-Dependent Mechanisms of Homeostatic Nuclear Positioning. Methods in molecular biology (Clifton, N.J.) 2018. link 12 Park IS, Jo KS, Won HS, Kim H. Dimerization of TRAF-interacting protein (TRAIP) regulates the mitotic progression. Biochemical and biophysical research communications 2015. link 13 Silva MC, Bodor DL, Stellfox ME, Martins NM, Hochegger H, Foltz DR et al.. Cdk activity couples epigenetic centromere inheritance to cell cycle progression. Developmental cell 2012. link 14 Gu J, Ruan X, Huang Z, Chen J, Zhou J. Identification of functional domains of chicken interleukin 2. Veterinary immunology and immunopathology 2010. link 15 Chan F, Sun C, Perumal M, Nguyen QD, Bavetsias V, McDonald E et al.. Mechanism of action of the Aurora kinase inhibitor CCT129202 and in vivo quantification of biological activity. Molecular cancer therapeutics 2007. link 16 Feng J, Huang H, Yen TJ. CENP-F is a novel microtubule-binding protein that is essential for kinetochore attachments and affects the duration of the mitotic checkpoint delay. Chromosoma 2006. link 17 Bhattacharya N, Wang Z, Davitt C, McKenzie IF, Xing PX, Magnuson NS. Pim-1 associates with protein complexes necessary for mitosis. Chromosoma 2002. link 18 Bönig H, Packeisen J, Röhne B, Hempel L, Hannen M, Klein-Vehne A et al.. Interaction between interleukin 10 and interleukin 6 in human B-cell differentiation. Immunological investigations 1998. link 19 Tugendreich S, Tomkiel J, Earnshaw W, Hieter P. CDC27Hs colocalizes with CDC16Hs to the centrosome and mitotic spindle and is essential for the metaphase to anaphase transition. Cell 1995. link90336-4) 20 Willingham MC, Bhalla K. Transient mitotic phase localization of bcl-2 oncoprotein in human carcinoma cells and its possible role in prevention of apoptosis. The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society 1994. link 21 Bailly E, Pines J, Hunter T, Bornens M. Cytoplasmic accumulation of cyclin B1 in human cells: association with a detergent-resistant compartment and with the centrosome. Journal of cell science 1992. link 22 Kim KJ, Alphonso M, Schmelzer CH, Lowe D. Detection of human leukemia inhibitory factor by monoclonal antibody based ELISA. Journal of immunological methods 1992. link90005-e) 23 Balczon R, Accavitti MA, Brinkley BR. Identification of a 40 x 10(3) Mr centromere-associated protein in cultured mammalian cells. Journal of cell science 1990. link 24 Gasser SM, Laemmli UK. Improved methods for the isolation of individual and clustered mitotic chromosomes. Experimental cell research 1987. link90334-x) 25 Duijvestijn AM, Kerkhove M, Bargatze RF, Butcher EC. Lymphoid tissue- and inflammation-specific endothelial cell differentiation defined by monoclonal antibodies. Journal of immunology (Baltimore, Md. : 1950) 1987. link 26 Drexler HG, Menon M, Gaedicke G, Minowada J. Expression of FMC7 antigen and tartrate-resistant acid phosphatase isoenzyme in cases of B-lymphoproliferative diseases. European journal of cancer & clinical oncology 1987. link90420-2) 27 Kamei H. A monoclonal antibody to chicken gizzard desmin that recognizes intermediate filaments and nuclear granules in BHK21/C13 cells. Cell structure and function 1986. link 28 Stanton TH, Maynard M, Bomsztyk K. Effect of interleukin-1 on intracellular concentration of sodium, calcium, and potassium in 70Z/3 cells. The Journal of biological chemistry 1986. link 29 Kuo LM, Robb RJ. Structure-function relationships for the IL 2-receptor system. I. Localization of a receptor binding site on IL 2. Journal of immunology (Baltimore, Md. : 1950) 1986. link 30 Finke JH, Scott J, Gillis S, Hilfiker ML. Generation of alloreactive cytotoxic T lymphocytes: evidence for a differentiation factor distinct from IL 2. Journal of immunology (Baltimore, Md. : 1950) 1983. link 31 Rao PE, Talle MA, Kung PC, Goldstein G. Five epitopes of a differentiation antigen on human inducer T cells distinguished by monoclonal antibodies. Cellular immunology 1983. link90119-3)

Diffuse low grade B-cell lymphoma